Alvotech (NasdaqGM:ALVO) just lined up fresh funding, amending its credit agreement to secure a new US$75 million term loan facility alongside earlier equity capital, giving the company access to US$240 million in new capital.

Despite the fresh US$240 million in available capital, Alvotech’s share price has been under pressure, with the stock down 27.8% year to date and the 1 year total shareholder return declining 60.7%, indicating weak recent momentum.

If this kind of funding driven story has your attention, it can be useful to compare with other companies using the Simply Wall St screener for 40 healthcare AI stocks

With Alvotech trading at US$3.61, sitting on access to US$240 million in fresh capital and screening as undervalued on several measures, the key question is whether this is a reset entry point or whether the market already reflects its future potential.

Most Popular Narrative: 73.9% Undervalued

Alvotech's most followed narrative places fair value at about $13.83 per share versus the last close at $3.61, which frames the recent funding against a much higher implied long term potential.

Ongoing launch and approval pipeline activity, including upcoming regulatory decisions in major global markets (for AVT03, AVT05, AVT23, and others), positions the company to tap into blockbuster biologic markets coming off patent, potentially driving a step change in topline revenue once approvals are secured.

Want to see what is built into that fair value for Alvotech? The narrative leans heavily on ambitious revenue compounding, sharper margins, and a richer future earnings multiple. The exact mix of those levers might surprise you.

Result: Fair Value of $13.83 (UNDERVALUED)

However, investors still need to weigh the risk that any further regulatory delays or tougher pricing in key biosimilar markets could quickly weaken the Alvotech narrative.

Next Steps

With both risks and rewards in play around Alvotech, do you want an outside view or your own? Act quickly, review the balance of issues and opportunities, and then decide where you stand using the 3 key rewards and 2 important warning signs

Looking for more investment ideas beyond Alvotech?

If you stop with just Alvotech, you could miss stocks that better match your goals, so take a few minutes to widen your opportunity set using these ideas.

• Target value first and see which companies combine quality metrics with attractive pricing through the 44 high quality undervalued stocks.
• Prioritise resilience by focusing on businesses that pair lower risk profiles with steadier fundamentals using the 74 resilient stocks with low risk scores.
• Hunt for potential future standouts by scanning a screener containing 18 high quality undiscovered gems that many investors may not be watching yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.